The various effects of four H1-antagonists on serum substance P levels in patients with atopic dermatitis

Journal of Dermatology

Volumn 32, Issue 10, 2005, Pages 776-781

  Izu, Kunio ^a   Tokura, Yoshiki ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

Atopic dermatitis; H1 antagonist; Olopatadine; Substance P

Indexed keywords

ANTIALLERGIC AGENT; BIOCHEMICAL MARKER; CETIRIZINE; CORTICOSTEROID; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; FEXOFENADINE; HISTAMINE H1 RECEPTOR ANTAGONIST; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 2 RECEPTOR; LACTATE DEHYDROGENASE; OLOPATADINE; SUBSTANCE P; TACHYKININ; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; ARTICLE; ATOPIC DERMATITIS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; EOSINOPHIL; FEMALE; HUMAN; MALE; PROTEIN BLOOD LEVEL; PROTEIN SECRETION;

EID: 28244482649     PISSN: 03852407     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1346-8138.2005.tb00844.x     Document Type: Article

References (20)

1. Simons FE, Simons KJ: The pharmacology and use of H1-receptor-antagonist drugs, N Engl J Med, 330: 1663-1670, 1994.
2. Albanesi C, Pastore S, Fanales-Belasio E, Girolomani G: Cetirizine and hydrocortisone differneally regulate ICAM-1 expression and chemokine release in cultured human keratinocytes, Clin Exp Allergy, 28: 101-109, 1998.
3. Abdelaziz MM, Devalia JL, Khair OA, Bayram H, Prior AJ, Davies RJ: Effect of fexofenadine on eosinophil-induced changes in epithelial permeability and cytokine release from nasal epithelial cells of patients with seasonal allergic rhinitis, J Allergy Clin Immunol, 101: 410-420, 1998.
4. Hamid Q, Boguniewicz M, Leung DYM: Differential in situ cytokine gene expression in acute versus chronic atopic dermatitis, J Clin Invest, 94: 870-876, 1994.
5. Leung DY, Boguniewicz M, Howell MD, Nomura I, Hamid QA: New insights into atopic dermatitis, J Clin Invest, 113: 651-657, 2004.
6. Matsunaga T, Katayama I, Yokozeki H, Nishioka K: ICAM-1 expression on keratinocytes in mechanically-injured skin of a patient with atopic dermatitis, J Dermatol Sci, 12: 219-226, 1996.
7. Kobayashi M, Tokura Y: Preferential downmodulation of certain chemokines by fexofenadine in human keratinocytes, J Dermatol Sci, 38: 67-69, 2005.
8. Wahlgren CF: Itch and atopic dermatitis: an overview, J Dermatol, 26: 770-779, 1999.
9. Heyer G, Groene D, Martus P: Efficacy of naltrexone on acetylcholine-induced alloknesis in atopic eczema, Exp Dermatol, 11: 448-455, 2002.
10. Stander S, Steinhoff M, Schmelz M, Weisshaar E, Metze D, Luger T: Neurophysiology of pruritus: Cutaneous elicitation of itch, Arch Dermatol, 139: 1463-1470, 2003.
11. Scholzen T, Armstrong CA, Bunnett NW, Luger TA, Olerud JE, Ansel JC: Neuropeptides in the skin: Interactions between the neuroendocrine and the skin immune system, Exp Dermatol, 7: 81-96, 1998.
12. Payan DG, Brewster DR, Goetzl EJ: Specific stimulation of human T lymphocytes by substance P, J Immunol, 131: 1613-1615, 1983.
13. Giuliani S, Maggi CA: Inhibition of tachykinin release from peripheral endings of sensory nerves by nociceptin, a novel opioid peptide, Br J Pharmacol, 118: 1567-1573, 1996.
14. Hanifin JM, Rajka G: Diagnostic features of atopic dermatitis, Acta Derm Venereol, 92: 44-47, 1980.
15. European Task Force on Atopic Dermatitis: Severity scoring of atopic dermatitis: The SCORAD index, Dermatology, 186: 23-31, 1993.
16. Joyce TJ, Yood RA, Carraway RE: Quantitation of substance-P and its metabolites in plasma and synovial fluid from patients with arthritis, J Clin Endocrinol Metab, 77: 632-637, 1993.
17. Ikemura T, Okarmura K, Sasaki Y, Ishi H, Ohmori K: KW-4679-induced inhibition of tachykininergic contraction in the guinea-pig bronchi by prejunctional inhibition of peripheral sensory neves, Br J Pharmacol, 117: 967-973, 1996.
18. Tuckett RP: Neurophysiology and neuroanatomy of pruritus, Bernhard JD (ed): Itch-Mechanisms and Management of Pruritus, McGraw-Hill, New York, 1994, pp 1-22.
19. Saito T, Hagihara A, Igarashi N, et al: Inhibitory effects of emedastine difumarate on histamine release, Jpn J Pharmacol, 62: 137-143, 1993.
20. Tokura Y, Kobayashi M, Ito T, Takahashi H, Matsubara A, Takigawa M: Anti-allergic drug olopatadine suppresses murine contact hypersensitivity and downmodulates antigen-presenting ability of epidermal Langerhans cells, Cell Immunol, 22: 47-54, 2003.